Comments on: Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy

Comments on: Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy https://www.novumpr.nl/2017/11/15/key-sub-analyses-of-re-dual-pci-showed-large-reductions-in-the-incidence-of-bleeding-complications-if-pradaxa-dabigatran-etexilate-dual-therapy-was-used-instead-of-warfarin-triple-the/?utm_source=rss&utm_medium=rss&utm_campaign=key-sub-analyses-of-re-dual-pci-showed-large-reductions-in-the-incidence-of-bleeding-complications-if-pradaxa-dabigatran-etexilate-dual-therapy-was-used-instead-of-warfarin-triple-the NovumPR press releases Wed, 15 Nov 2017 14:44:22 +0000 hourly 1 https://wordpress.org/?v=6.8.3